|Bid||3.2500 x 800|
|Ask||3.2600 x 1200|
|Day's Range||3.2000 - 3.3900|
|52 Week Range||3.1000 - 9.9500|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
One Triangle drug-maker is feeling confident following a successful Phase III trial – despite some less confident investors pulling the stock down nearly 50 percent.
BioCryst announced Tuesday that a Phase 3 study dubbed APeX-2, which is evaluating once-daily, oral BCX7353 — a selective inhibitor of plasma kallikrein — in preventing hereditary angioedema, or HAE, attacks, met the primary endpoint for both the 110mg and 150mg dose levels. The primary efficacy endpoint is the rate of investigator-confirmed angioedema attacks over 24 weeks of study drug administration. The 110mg dose of BCX7353 reduced the HAE attack rate by 30 percent compared to placebo and the 150mg dose reduced the attack rate by 44 percent.
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) delivered earnings and revenue surprises of 0.00% and 101.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its latestRead More...
It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results and M&A news flow . View more earnings on XBI Now, here are the upcoming week's ...
Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions. Among the noteworthy developments of the week: The FDA panel ruling ...
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
On Nov. 6, detailing the company's third quarter earnings to a handful of analysts, BioCryst Pharmaceuticals' longtime CEO, Jon Stonehouse, said he sees 2019 to be a transformative year for the company.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
BioCryst (BCRX) delivered earnings and revenue surprises of -12.00% and -42.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?